PDCD1 and neoplasm: Although other reports have explored the effectiveness of nanoplatforms conjugated with antibodies or engineered vesicles to disrupt the PD1/PDL1 inhibitory axis [2, 21, 56, 57, 61–63], studies using BNPs to selectively target cancer cells through immune exhaustion [16, 17], and exploiting tumor IE, are lacking.